In this trial we use the LMWH Tinzaparin. Tinzaparin is a drug which has already been used for many years in the prevention or treatment of VTE, also in pregnant women. It is given once daily via a subcutaneous injection.
Approximately 850 to 1100 patients will be taking part in this trial, receiving various different types of LMWH.